September 2026 Research Update

This month added a clearer long-term picture of how Friedreich ataxia can affect the heart: early on, the heart often looks mildly thickened while pumping still looks normal, but over time pumping strength can decline. The study also found that genetics (GAA repeat length) and certain early heart scan measurements helped separate people who later developed more serious heart outcomes from those who did not. This matters because it frames Friedreich ataxia heart disease as something that can change in stages, rather than staying the same over time. [1]

In a large retrospective group followed through echocardiograms, longer GAA1 repeat length was linked to later rhythm problems (arrhythmias) and later reduced ejection fraction (a measure of how well the heart pumps). The study also reported that early increases in heart wall thickness and an unusually high ejection fraction on early scans were signals that later bad outcomes were more likely, including arrhythmias, pumping decline, and death. Because these data came from past medical records across sites, the results describe patterns seen in this cohort rather than proving that one early finding directly causes later outcomes. [1]

For patients and caregivers, this research mainly helps set expectations about what heart involvement can look like across time in Friedreich ataxia, and it highlights that genetic severity (GAA repeat length) tracked with higher cardiac risk in this dataset. It does not introduce a new treatment, but it supports the idea that early heart scan features may help research studies sort people by risk and better understand who tends to develop rhythm problems or weaker pumping later. What remains uncertain is how well these specific scan signals will predict outcomes for any one individual, especially because the echocardiograms were not centrally re-read and some heart measures (like relaxation/diastolic function) were often missing. [1]

This month strengthened the idea that Friedreich ataxia does not look the same on MRI for everyone, even when people have similar disease duration or similar changes on clinical exams. When researchers tracked brain, brainstem, and spinal cord scans over time, they could group participants into different progression patterns, including patterns where microscopic tissue changes seemed to lead and others where larger-scale shrinkage was more prominent. The clearest separator between these patterns was GAA repeat length, not how long someone had been diagnosed. [2]

In this longitudinal imaging work, three main progression patterns were reported among robust clusters: microstructure-dominant change, macrostructure-dominant change, and minimal measurable change, with a fourth cluster also identified. The minimal-progression pattern was more common in healthy controls, while the other patterns were more common in people with Friedreich ataxia. Larger GAA1 expansions were especially enriched in the microstructure-dominant group, suggesting that repeat length may relate to the kind of nervous system change that shows up on scans, even when clinical progression rates did not distinguish the groups. [2]

For patients, this research mainly adds understanding rather than changing care now: it suggests there may be different underlying "scan trajectories" in Friedreich ataxia that are not captured well by disease duration alone. In the future, if confirmed, these scan-based groupings could help research trials measure change more precisely or help explain why two people can have different scan findings despite similar day-to-day symptoms. What remains uncertain is how these MRI patterns relate to future disability or specific symptoms, because the study reported that clinical progression did not separate the groups even when MRI patterns differed. [2]

This month included an experimental mouse study that tested a bold idea: treating Friedreich ataxia by replacing certain immune cells and letting them share healthy mitochondria (the cell's energy producers) with affected tissues. In the mouse model, this approach was linked to better energy-related signals inside cells and partial improvements in both neurologic and heart measures. Because this was animal research with specialized transplant procedures, it should be viewed as a proof-of-concept rather than evidence of a human treatment. [3]

Researchers used conditioning plus a bone marrow transplant approach to achieve high replacement of microglia/macrophages in the brain, and they observed transfer of donor mitochondria into nervous system cells and heart muscle cells. In these mice, the study reported increased activity of genes involved in energy production and improved mitochondrial function, along with partial improvements in growth, movement/coordination tests, heart ultrasound measures, and survival (53% to 80% in one reported comparison). The authors also reported no treatment-related toxicities during the study period, while noting that the rescue was incomplete and that translation to humans would require caution. [3]

For patients and caregivers, this study mainly matters as early-stage research that explores a new biological strategy, not as something ready for clinical use. It helps clarify that mitochondrial transfer between cells can happen in a living Friedreich ataxia model and that boosting cellular energy pathways might improve both nerve-related and heart-related features in that model. What remains uncertain is whether a similar approach could be done safely and effectively in people, especially because it relied on intensive transplant conditioning and most detailed mouse testing emphasized a female cohort. [3]